BRIAN GERONDALE: Open Payments
NPI 1548250509 · GRAND RAPIDS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,576 in 64 payments from 16 companies in 2025. Trend: 2023 $1,507 · 2024 $1,498 · 2025 $1,576
Food & beverage: $1,576
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $340 |
| GENZYME CORPORATION | 9 | $204 |
| Janssen Biotech, Inc. | 3 | $175 |
| Regeneron Healthcare Solutions, Inc. | 8 | $171 |
| Incyte Corporation | 7 | $169 |
| UCB, Inc. | 4 | $119 |
| PFIZER INC. | 5 | $106 |
| Arcutis Biotherapeutics, Inc. | 2 | $75 |
| E.R. Squibb & Sons, L.L.C. | 1 | $64 |
| LEO Pharma Inc. | 2 | $40 |
Products named: DUPIXENT, TREMFYA, RINVOQ, OPZELURA, SKYRIZI, Bimzelx, EUCRISA, LIBTAYO.
Industry payments across MI — which companies pay providers there.
